Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 232.07B |
| Revenue (ttm) | 54.75B |
| Net Income (ttm) | 16.22B |
| Shares Out | n/a |
| EPS (ttm) | 6.44 |
| PE Ratio | 14.31 |
| Forward PE | 13.07 |
| Dividend | 2.86 (3.05%) |
| Ex-Dividend Date | Dec 15, 2025 |
| Volume | 1,661 |
| Average Volume | 5,425 |
| Open | 93.90 |
| Previous Close | 93.90 |
| Day's Range | 92.10 - 93.90 |
| 52-Week Range | 65.50 - 99.00 |
| Beta | 0.30 |
| RSI | 67.46 |
| Earnings Date | Feb 3, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Merck (MRK) Raises Revenue Forecast for New Growth Drivers
Merck (MRK) Raises Revenue Forecast for New Growth Drivers
Merck & Co Inc at JPMorgan Healthcare Conference Transcript
Merck & Co Inc at JPMorgan Healthcare Conference Transcript
Merck & Co., Inc. (MRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s
Merck said on Monday it has raised its outlook for new growth drivers, forecasting $70 billion in revenue from these fresh businesses by the mid-2030s, as it accelerates the launch of additional drugs...
Merck (MRK) Acquisition Talks with Revolution Medicines: Analyst's Perspective
Merck (MRK) Acquisition Talks with Revolution Medicines: Analyst's Perspective
Revolution Medicines (RVMD) Shares Dip Amid Merck Acquisition Rumors
Revolution Medicines (RVMD) Shares Dip Amid Merck Acquisition Rumors
Revolution Medicines declines to comment on M&A speculation at conference
Revolution Medicines (RVMD) declines to comment on Merck (MRK) M&A talks after $28B–$32B reports; RVMD stock dips post-surge.
Merck: FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's new dru...
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?
The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metr...
3 Dividend Stocks to Hold for the Next 10 Years
Contrary to a common assumption, the tobacco industry isn't exactly imploding. There's still money to be made here.
Sandisk, Bloom Energy, And Oklo Are Among the Top 10 Large-Cap Gainers Last Week (Jan. 5-Jan. 9): Are the Others in Your Portfolio?
A powerful mix of defense spending, AI infrastructure deals and takeover speculation sent several large-cap stocks sharply higher last week, reshaping the market's leaderboard . These ten large-cap st...
The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips
The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite. The index's top payers dish up to 6.8%.
Key deals this week: Merck, Glencore, CrowdStrike, Marvell Technology, Steel Dynamics and more
Notable analyst calls this week: Palantir, Merck and Lockheed Martin among top picks
January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its single share price. Analyst projections suggest the top ten Dow Dogs could delive...
Merck (MRK) Eyes Acquisition of Revolution Medicines (RVMD) for $30 Billion
Merck (MRK) Eyes Acquisition of Revolution Medicines (RVMD) for $30 Billion
Merck (MRK) Eyes $30 Billion Acquisition of Revolution Medicines
Merck (MRK) Eyes $30 Billion Acquisition of Revolution Medicines
Merck Reportedly in Talks to Acquire Revolution Medicines (RVMD)
Merck Reportedly in Talks to Acquire Revolution Medicines (RVMD)
Merck in talks to acquire Revolution Medicines for about $30B - WSJ
Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion
Revolution is developing drugs that target a molecular driver of cancers.
Trade Tracker: Kevin Simpson buys FedEx, SLB and sells a covered call on Merck
Kevin Simpson, founder and chief investment officer at Capital Wealth Planning , joins CNBC's "Halftime Report" to detail his latest portfolio moves.
Trade Tracker: Kevin Simpson buys FedEx, SLB and sells a covered call on Merck
Kevin Simpson, founder and chief investment officer at Capital Wealth Planning , joins CNBC's "Halftime Report" to detail his latest portfolio moves.
Healthy Returns: What to expect from pharma at the JPM conference
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Merck in Talks to Buy Revolution Medicines Per Financial Times Report
Merck is in talks to acquire RVMD, which could bolster its oncology pipeline, according to a Financial Times report.
Merck (MRK) Considers Multi-Billion Dollar Acquisition of Revolution Medicines (RVMD)
Merck (MRK) Considers Multi-Billion Dollar Acquisition of Revolution Medicines (RVMD)